Terbogrel

CAS : 149979-74-8

Ref. 3D-ZFA97974

Informations sur le produit

• Nom: Terbogrel
• Synonymes: (5E)-6-[3-[[(Cyanoamino)[(1,1-dimethylethyl)amino]methylene]amino]phenyl]-6-(3-pyridinyl)-5-hexenoic acid, 5-Hexenoic acid, 6-[3-[[(cyanoamino)[(1,1-dimethylethyl)amino]methylene]amino]phenyl]-6-(3-pyridinyl)-, (E)-, 5-Hexenoic acid, 6-[3-[[(cyanoamino)[(1,1-dimethylethyl)amino]methylene]amino]phenyl]-6-(3-pyridinyl)-, (5E)-, (5E)-6-[m-(3-tert-Butyl-2-cyanoguanidino)phenyl]-6-(3-pyridyl)-5-hexenoic acid

Description

Terbogrel is a chemical compound that has been used as a pharmaceutical agent. It is an ester of terbutaline and benzoic acid. Terbogrel is used to treat heparin-induced thrombocytopenia and to prevent deep vein thrombosis (DVT). The pharmacological mechanism of terbogrel is not fully elucidated, but it is believed that the drug increases the production of prostacyclin, which inhibits platelet aggregation. Terbogrel also has antioxidant properties due to its hydroxyl group that may be important for the prevention of oxidative injury in collagen synthesis. Terbogrel has been shown to have clinical relevance in primary pulmonary hypertension, which can be treated with this drug. Terbogrel binds to phosphodiesterase type-5, preventing the breakdown of cAMP and PDE-3. This binding leads to increased levels of cAMP, which stimulates protein kinase A (PKA

• Marque: Biosynth

Propriétés chimiques

• Masse moléculaire: 405.5 g/mol
• Formule: C₂₃H₂₇N₅O₂
• Degré de pureté: Min. 95%